- Home
- STSS vs ZVSA Comparison
STSS vs ZVSA Comparison
Compare STSS & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STSS
- ZVSA
- Stock Information
- Founded
- STSS 2017
- ZVSA 2014
- Country
- STSS United States
- ZVSA United States
- Employees
- STSS N/A
- ZVSA N/A
- Industry
- STSS Medical/Dental Instruments
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- STSS Health Care
- ZVSA Health Care
- Exchange
- STSS Nasdaq
- ZVSA Nasdaq
- Market Cap
- STSS 3.0M
- ZVSA 3.5M
- IPO Year
- STSS 2022
- ZVSA N/A
- Fundamental
- Price
- STSS $0.32
- ZVSA $1.29
- Analyst Decision
- STSS
- ZVSA Strong Buy
- Analyst Count
- STSS 0
- ZVSA 1
- Target Price
- STSS N/A
- ZVSA $240.00
- AVG Volume (30 Days)
- STSS 2.4M
- ZVSA 2.1M
- Earning Date
- STSS 03-31-2025
- ZVSA 03-24-2025
- Dividend Yield
- STSS N/A
- ZVSA N/A
- EPS Growth
- STSS N/A
- ZVSA N/A
- EPS
- STSS N/A
- ZVSA N/A
- Revenue
- STSS N/A
- ZVSA N/A
- Revenue This Year
- STSS N/A
- ZVSA N/A
- Revenue Next Year
- STSS N/A
- ZVSA N/A
- P/E Ratio
- STSS N/A
- ZVSA N/A
- Revenue Growth
- STSS N/A
- ZVSA N/A
- 52 Week Low
- STSS $0.30
- ZVSA $0.98
- 52 Week High
- STSS $18.15
- ZVSA $25.00
- Technical
- Relative Strength Index (RSI)
- STSS 12.70
- ZVSA 51.27
- Support Level
- STSS $0.34
- ZVSA $1.33
- Resistance Level
- STSS $0.42
- ZVSA $1.54
- Average True Range (ATR)
- STSS 0.13
- ZVSA 0.12
- MACD
- STSS -0.15
- ZVSA -0.01
- Stochastic Oscillator
- STSS 1.12
- ZVSA 20.00
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes are designed to eliminate potentially infectious and accidental needlestick injuries.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.